Table 1.

Characteristics of advanced non-small-cell lung cancer patients treated with first-line single-agent immune checkpoint inhibitors.

Characteristics	No. of patients (n = 40)
Age (years), median (range)	66 (31–77)
Sex, n (%)
Male	33 (83)
Female	7 (17)
Smoking history, n (%)
Current/former	24 (60)
Never	16 (40)
Pathology, n (%)
Non-squamous	28 (70)
Squamous	12 (30)
PD-L1, n (%)
>50% and <75%	18 (45)
≥75%	22 (55)
Number of metastatic sites, n (%)
1	13 (33)
2	16 (40)
≥3	11 (27)
Baseline adrenal metastasis, n (%)
Yes	10 (25)
No	30 (75)
Baseline brain metastasis, n (%)
Yes	12 (30)
No	28 (70)
Baseline bone metastasis, n (%)
Yes	14 (35)
No	26 (65)
Baseline liver metastasis, n (%)
Yes	8 (20)
No	32 (80)
Baseline contralateral lung metastasis, n (%)
Yes	10 (25)
No	30 (75)
Baseline pleural metastasis, n (%)
Yes	10 (25)
No	30 (75)